Clinical trials: Chest--Diseases
Non-Small Cell Lung Cancer (NSCLC)
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04921358
- Testing
- Tislelizumab, Docetaxel, Sitravatinib
- Where
- 61 sites in Australia, China
- Volunteers
- 377 people
- Sponsor
- BeiGene
Lung Neoplasms, Respiratory Failure
Clearance Of Mucus In Stents (COMIS)
The goal of this clinical research study is to compare the effects of sodium bicarbonate to normal saline when used for clearing mucus blockage in patients with airway stents.
- Conditions
- Lung Neoplasms, Respiratory Failure, Pneumonia, Acute Coronary Syndromes
- Trial name
- NCT01370278
- Testing
- Normal Saline, Sodium Bicarbonate
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
This study is a phase II single-arm clinical study.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in…
- Trial name
- NCT04425135
- Testing
- Camrelizumab, Apatinib, Pemetrixed
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Carcinoma, Non-Small-Cell Lung
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or…
- Trial name
- NCT03181308
- Testing
- Carotuximab (TRC105), OPDIVO
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Stage Ib Lung Carcinoma
Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma
Researchers developed the nomogram which evaluate the risk of recurrence after surgical resection, and found that the stage 1 NSCLC patients with more than 104 point of nomogram showed similar recurrence rate to the recurrence…
- Trial name
- NCT02281708
- Testing
- vinorelbine plus cisplatin
- Where
- South Korea
- Volunteers
- 1,012 people
- Sponsor
- Seoul National University Hospital
Lung Cancer
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
To test the impact of a multilevel intervention on primary (provider-patient communication, intentions, and knowledge) and secondary (screening referrals and completion) outcomes.
- Trial name
- NCT04675476
- Testing
- Provider Prompt & Patient Outreach and Education
- Where
- United States
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Georgetown University
Shortness of Breath
Effects of Incentive Spirometry on Dyspnea and Chest Clearance in Asthmatic Patients During Seasonal Smog
EFFECTS OF INCENTIVE SPIROMETRY ON DYSPNEA AND CHEST CLEARANCE IN ASTHMATIC PATIENTS DURING SEASONAL SMOG
- Trial name
- NCT05586217
- Testing
- INCENTIVE SPIROMETRY, Active cycle of breathing
- Where
- Pakistan
- Volunteers
- 41 people
- Sponsor
- Riphah International University
Lung Cancer
Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer
This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer and their families.
- Trial name
- REACH PC (NCT03375489)
- Testing
- Telehealth Palliative Care, In-person Palliative Care
- Where
- 23 sites in United States
- Volunteers
- 1,798 people
- Sponsor
- Massachusetts General Hospital
Cancer of the Lung
Microwave Ablation in Chinese Patients With Lung Tumors
Adult patients with non-small cell lung cancer (NSCLC) or oligometastatic lung tumors will all receive microwave ablation (MWA) performed percutaneously by doctors who are experienced in lung tumor ablation.
- Trial name
- NCT04889989
- Testing
- Microwave Ablation
- Where
- 8 sites in China
- Volunteers
- 13 people
- Sponsor
- Ethicon, Inc.
Non-small Cell Lung Cancer
Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC
In this study, the investigators will investigate toxicity in patients treated with a Programmed cell death protein 1 (PD-1) inhibitor and radiotherapy.
- Trial name
- COM-IT-1 (NCT03644823)
- Testing
- Atezolizumab, Radiotherapy
- Where
- Norway
- Volunteers
- 21 people
- Sponsor
- Oslo University Hospital
Lung Cancer
Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
The proposed study seeks to address a critical gap in the management of lorlatinib-induced metabolic derangements, particularly rapid weight gain, which can adversely affect treatment adherence, dosing and ultimately patient…
- Trial name
- NSCLC (NCT07782359)
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Lung Cancer
Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy
Thoracic surgery correlates with significant pain in postoperative period. In order to alleviate the pain various combinations of pharmaceuticals and administration methods are employed.
- Trial name
- NCT02040662
- Testing
- Continuous Thoracic Epidural Block, Continuous Thoracic Paravertebral Block, Patient-Controlled Analgesia with Morphine
- Where
- Poland
- Volunteers
- 120 people
- Sponsor
- Pulmonary Hospital Zakopane
Low-dose Radiotherapy, Tumor Microenvironment
Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy
The purpose of this phase Ⅱ trial was to investigate the effect of low-dose radiotherapy (LDRT) on the tumor immune microenvironment (TME) in oligometastasis, oligoprogression, and oligopersistence of non-small cell lung cancer…
- Conditions
- Low-dose Radiotherapy, Tumor Microenvironment, Non-Small Cell Lung Cancer
- Trial name
- NCT06331585
- Testing
- low dose radiotherapy
- Where
- China
- Sponsor
- Hetian District People's Hospital
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
The REVEALPLAQUE Study: A pRospEctiVe, multicEnter Study to AnaLyze PLAQUE Using CCTA
This study will evaluate the level of agreement between noninvasive CCTA (coronary computed tomography angiography)-based quantification and characterization of coronary atherosclerosis and invasive IVUS (intravascular…
- Trial name
- REVEALPLAQUE (NCT05138289)
- Testing
- Total Plaque Volume
- Where
- United States
- Volunteers
- 258 people
- Sponsor
- HeartFlow, Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
- Trial name
- NCT05048797
- Testing
- Trastuzumab Deruxtecan, Cisplatin, Carboplatin
- Where
- 130 sites in United States, Austria and 18 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)
The objective of this pharmacoeconomics (PE) study is to evaluate the cost- effectiveness analysis and cost-utility analysis of IRESSA® as first line treatment of NSCLC from the society perspective, based on resources and…
- Trial name
- NCT00173524
- Testing
- PharmacoEconomic Assessment
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer
Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage…
- Trial name
- NCT00444223
- Testing
- fluorine F 18 FEQA + positron emission tomography
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain Cancer, Brain Metastases
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that…
- Conditions
- Brain Cancer, Brain Metastases, Melanoma, Lung Cancer
- Trial name
- NCT04899908
- Testing
- Stereotactic Radiation, AGuIX gadolinium-based nanoparticles
- Where
- 2 sites in United States
- Volunteers
- 134 people
- Sponsor
- Brigham and Women's Hospital
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.